Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026)

Regeneron Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $104.0 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 8.0% year-over-year to $104.0 million in Q1 2026; TTM through Mar 2026 was $733.5 million, a 51.27% increase from a year earlier, with the FY2025 full-year figure at $725.8 million, up 97.6% from the prior year.
• Tax Provisions fell to $104.0 million in Q1 2026 per REGN's latest filing, from $199.1 million in the prior quarter.
• Across five years, Tax Provisions topped out at $303.3 million in Q3 2025 and bottomed at -$21.3 million in Q1 2024.
• The 5-year median for Tax Provisions is $111.1 million (2022), against an average of $115.5 million.
• Across the five-year window, Tax Provisions slumped 152.99% in 2024 and soared 552.11% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $127.6 million in 2022, then sank by 109.4% to -$12.0 million in 2023, then jumped by 436.67% to $40.4 million in 2024, then jumped by 392.82% to $199.1 million in 2025, then tumbled by 47.76% to $104.0 million in 2026.
• Per Business Quant, the three latest REGN Tax Provisions figures stand at $104.0 million (Q1 2026), $199.1 million (Q4 2025), and $303.3 million (Q3 2025).